GO BACK TO FERTILITY.COM
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
You can find detailed explanation about how ONE works below.
Oocyte Number Estimator - ONE
ONE estimates the minimum number of mature oocytes needed for obtaining at least one euploid blastocyst.
How ONE works
ONE (Oocyte Number Estimator) is a tool based on the ART Calculator predictive model published by Prof. S. Esteves 1,2. ONE provides personalized information to facilitate treatment expectation discussion, communication and planning between healthcare professionals and patients. The application can be used in two different settings: pre-treatment and post-treatment.
Pre-treatment
The model estimates the number of mature (MII) oocytes needed to obtain at least one euploid blastocyst for transfer in infertile couples undergoing Assisted Reproductive Technology.
Post-treatment
The model computes a revised estimate of probability of obtaining at least one euploid embryo when the number of mature oocytes obtained after one or more oocyte retrieval cycles is provided.
Disclaimer
The ONE application offered by Merck KGaA, Darmstadt, Germany is not classified as a medical device according to the International Medical Device Regulators Forum (IMDRF) definition. The ONE application is not intended for clinical, diagnostic, or therapeutic purposes. Users of the application are encouraged to consult qualified healthcare professionals and refer to approved medical devices, guidelines and protocols when making clinical decisions or providing medical care. The content, analyses, and recommendations generated by the ONE application are meant for informational purposes only and must not be used by healthcare professionals as the sole basis for clinical decision-making or patient care.
Merck KGaA, Darmstadt, Germany and its affiliates exclude any liability for the accuracy, reliability, or completeness of the application's information or any consequences resulting from its use.
Limitations to the ONE application acknowledged in its publications include the inherent bias of the retrospective data used to develop the tool, variability among centers, and model performance.
The ONE application is designed so that individual searches are not linkable to an individual user. Individual search histories are not recorded. For further information on how your personal data is processed in using our website, please check the Website Privacy Statement.
GL-NONF-02626 May 2024
Reference
COLLAPSE ALL1.
Esteves SC, Carvalho JF, Bento FC, Santos J. A Novel Predictive Model to Estimate the Number of Mature Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection: The ART Calculator. Front Endocrinol (Lausanne). 2019 Feb 28;10:99. doi: 10.3389/fendo.2019.00099.
2.
Esteves SC, Yarali H, Ubaldi FM, Carvalho JF, Bento FC, Vaiarelli A, Cimadomo D, Özbek İY, Polat M, Bozdag G, Rienzi L, Alviggi C. Validation of ART Calculator for Predicting the Number of Metaphase II Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection. Front Endocrinol (Lausanne). 2020 Jan 24;10:917. doi: 10.3389/fendo.2019.00917.
This is an international website for Healthcare Professionals outside of United States, Canada, Puerto Rico, UK and Ireland.
Information on this site is from the Summary of Product Characteristics (SmPC) for Pergoveris®, GONAL-f®, Luveris®, Crinone®, OVITRELLE®/OVIDREL®, and Cetrotide® in the EU. Registration status and approved product labels may vary according to specific country.
Connect with us
Find the Healthcare Business of Merck on:
GL-NONF-02626 May 2024
Copyright 2024 Merck KGaA, Darmstadt, Germany